Magazine Article | January 4, 2022

How Will The CGT Manufacturing Paradigm Mature In 2022?

Source: Life Science Leader

By Anna Rose Welch, Director, Cell & Gene Collaborative
Subscribe to my blog ARW on CGT here!

Eye-opening. Heterogenous. Challenging. Changeable.

To Robert Hariri, CEO of Celularity; Matthew Durdy, CEO of the Cell and Gene Therapy Catapult; Beth White, CBO & SVP operations of Renovacor; and Geoffrey Glass, CEO of Kiniciti, the past year in the cell and gene therapy (CGT) manufacturing space has been all of these adjectives — and more.

VIEW THE MAGAZINE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader